JPH05505941A - オリゴヌクレオチド―輸送剤ジスルフィド結合体 - Google Patents

オリゴヌクレオチド―輸送剤ジスルフィド結合体

Info

Publication number
JPH05505941A
JPH05505941A JP91508586A JP50858691A JPH05505941A JP H05505941 A JPH05505941 A JP H05505941A JP 91508586 A JP91508586 A JP 91508586A JP 50858691 A JP50858691 A JP 50858691A JP H05505941 A JPH05505941 A JP H05505941A
Authority
JP
Japan
Prior art keywords
oligonucleotide
carrier
nucleic acid
cell
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP91508586A
Other languages
English (en)
Japanese (ja)
Inventor
ラサム，ジョン　エー．
リン，クエイ―ユン
マテウッチ，マーク
Original Assignee
ギリード　サイエンシズ　インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリード　サイエンシズ　インコーポレーテッド filed Critical ギリード　サイエンシズ　インコーポレーテッド
Publication of JPH05505941A publication Critical patent/JPH05505941A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP91508586A 1990-03-29 1991-03-29 オリゴヌクレオチド―輸送剤ジスルフィド結合体 Pending JPH05505941A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50236190A 1990-03-29 1990-03-29
US502,361 1990-03-29
PCT/US1991/002224 WO1991014696A1 (fr) 1990-03-29 1991-03-29 Conjugues a base de disulfure d'oligonucleotide et d'un agent de transport

Publications (1)

Publication Number Publication Date
JPH05505941A true JPH05505941A (ja) 1993-09-02

Family

ID=23997461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP91508586A Pending JPH05505941A (ja) 1990-03-29 1991-03-29 オリゴヌクレオチド―輸送剤ジスルフィド結合体

Country Status (5)

Country Link
EP (1) EP0537299A1 (fr)
JP (1) JPH05505941A (fr)
AU (1) AU7759291A (fr)
CA (1) CA2079109A1 (fr)
WO (1) WO1991014696A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534521A (ja) * 2010-06-22 2013-09-05 デエヌア・テラプーティック 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化ｉｎｖｉｖｏ送達システム
JP2014516977A (ja) * 2011-05-27 2014-07-17 アンスティテュ・キュリ 二本鎖切断を模倣するｄｎａ分子と温熱療法との組み合わせによるガンの処置
JP2015062421A (ja) * 2006-07-12 2015-04-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達
JP2016537027A (ja) * 2013-11-06 2016-12-01 ソルスティス バイオロジクス，リミティッド ジスルフィド基を有するポリヌクレオチド構築物
WO2019039403A1 (fr) * 2017-08-22 2019-02-28 国立大学法人名古屋大学 Polynucléotide modifié
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US11981703B2 (en) 2016-08-17 2024-05-14 Sirius Therapeutics, Inc. Polynucleotide constructs

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6783931B1 (en) 1990-01-11 2004-08-31 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5852182A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals Inc. Thiol-derivatized oligonucleosides
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US5578718A (en) * 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6831166B2 (en) 1992-10-23 2004-12-14 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JP2823959B2 (ja) * 1991-10-24 1998-11-11 アイシス・ファーマシューティカルス・インコーポレーテッド 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5780444A (en) * 1991-12-13 1998-07-14 Trustees Of Princeton University Compositions and methods for cell transformation
US5849905A (en) * 1994-11-23 1998-12-15 Centre National De La Recherche Scientifique Biologically active phosphotriester-type nucleosides and methods for preparing same
US5770725A (en) * 1992-05-25 1998-06-23 Gosselin; Gilles Phosphotriester type biologically active compounds
US6020482A (en) * 1992-05-25 2000-02-01 Gosselin; Gilles Phosphotriester type biologically active compounds
FR2691463A1 (fr) * 1992-05-25 1993-11-26 Centre Nat Rech Scient Dérivés nucléotidiques, leur préparation et leur application en thérapeutique.
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994023751A1 (fr) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Peptides de tranfert d'acides nucleiques et leur utilisation pour injecter des acides nucleiques dans des cellules eucaryotes
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US5580972A (en) * 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
WO1995007092A1 (fr) * 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Vecteurs de transport d'agents neurologiques traversant la barriere hemato-encephalique
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
DE4421079C1 (de) * 1994-06-16 1995-08-17 Peter Dr Rer Nat Seibel Chimäres Peptid-Nukleinsäure-Fragment, Verfahren zu seiner Herstellung und die Verwendung des Fragments zur zielgerichteten Nukleinsäureeinbringung in Zellorganellen und Zellen
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
EP0888128A2 (fr) 1995-02-10 1999-01-07 The Worcester Foundation For Biomedical Research Apport de composes exogenes
WO1996030536A1 (fr) * 1995-03-24 1996-10-03 Board Of Regents, The University Of Texas System Apport d'un acide nucleique cible egf
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5959100A (en) * 1996-03-27 1999-09-28 Nexstar Pharmaceuticals, Inc. Pyrimidine nucleosides as therapeutic and diagnostic agents
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
CA2298067A1 (fr) * 1997-07-24 1999-02-04 Ulo Langel Conjugues de peptides transporteurs et analogues d'acides nucleiques ainsi que leur utilisation
WO1999006576A1 (fr) 1997-08-04 1999-02-11 Calydon, Inc. Sequence stimulatrice de la kallicreine glandulaire chez l'homme, vecteurs comprenant cette sequence et procedes d'utilisation de ces derniers
CN1289371A (zh) 1998-01-30 2001-03-28 阿文蒂斯药物股份有限公司 对还原条件敏感的转染化合物,含有它们的药物组合物及其应用
US6531590B1 (en) * 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
WO2000012530A1 (fr) * 1998-08-26 2000-03-09 Nexstar Pharmaceuticals, Inc. CLIVAGE DIRIGE SUR SITE dU DE CONJUGUES COVALENTS
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
WO2000034343A1 (fr) * 1998-12-04 2000-06-15 Mosaic Technologies, Inc. Methode d'immobilisation d'oligonucleotides
US6121437A (en) * 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6822086B1 (en) 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
WO2005041859A2 (fr) 2003-04-30 2005-05-12 Sirna Therapeutics, Inc. Conjugues et compositions
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AU2001238346A1 (en) * 2000-02-15 2001-08-27 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6706474B1 (en) 2000-06-27 2004-03-16 Board Of Trustees Of The University Of Illinois Nucleic acid enzyme biosensors for ions
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030148380A1 (en) 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US7179907B2 (en) 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
SE0201234D0 (sv) * 2002-04-24 2002-04-24 Avaris Ab Transfer complex with added functionality and methods for its use
US6890719B2 (en) 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
US20050064508A1 (en) 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US6913890B2 (en) 2002-12-18 2005-07-05 Palo Alto Research Center Incorporated Process for preparing albumin protein conjugated oligonucleotide probes
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
EP1667522B1 (fr) * 2003-09-09 2018-01-17 Geron Corporation Oligonucléotides modifiés destinés à l'inhibition de la télomérase
EP1695717A1 (fr) * 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport de structures nano-et macromoléculaires dans le cytoplasme et le noyau des cellules
US7892734B2 (en) 2005-08-11 2011-02-22 The Board Of Trustees Of The University Of Illinois Aptamer based colorimetric sensor systems
WO2007109500A1 (fr) 2006-03-16 2007-09-27 The Board Of Trustees Of The University Of Illinois Dispositifs à flux latéral
US8415461B2 (en) 2007-01-19 2013-04-09 The Board Of Trustees Of The University Of Illinois Amphiphilic substances and functionalized lipid vesicles including the same
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US8058415B2 (en) 2007-04-24 2011-11-15 The Board Of Trustees Of The University Of Illinois Aptamer- and nucleic acid enzyme-based systems for simultaneous detection of multiple analytes
US8409800B2 (en) 2007-07-16 2013-04-02 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for copper detection
US8568690B2 (en) 2007-07-31 2013-10-29 The Board Of Trustees Of The University Of Illinois MRI contrast agents and high-throughput screening by MRI
US8367416B2 (en) 2007-08-10 2013-02-05 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for mercury detection
US8062893B2 (en) 2008-10-10 2011-11-22 The Board Of Trustees Of The University Of Illinois Fluorescent sensor for mercury
EP3345915B1 (fr) 2010-04-12 2021-11-24 Somalogic, Inc. Pyramidines modifiés en position 5 et leur utilisation
US8815156B2 (en) 2010-07-19 2014-08-26 Andalyze, Inc. Sensor housing and reagent chemistry
EP2885313A4 (fr) 2012-08-20 2016-03-09 Univ California Polynucléotides possédant des groupes bioréversibles
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
IL264685B (en) 2016-08-23 2022-09-01 Dicerna Pharmaceuticals Inc Preparations containing reversibly modified oligonucleotides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
US4471113A (en) * 1982-02-03 1984-09-11 The United States Of America As Represented By The Department Of Energy Prodrugs based on phospholipid-nucleoside conjugates
CA1223831A (fr) * 1982-06-23 1987-07-07 Dean Engelhardt Nucleotides modifies, methodes de preparation et d'utilisation et composes les contenant
US4587044A (en) * 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
JPS638396A (ja) * 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4837311A (en) * 1987-06-22 1989-06-06 Hoffman-La Roche Inc. Anti-retroviral compounds
WO1989005853A1 (fr) * 1987-12-15 1989-06-29 Synthetic Genetics Conjugue de chelate d'acide nucleique utilise comme agent therapeutique et de diagnostic

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015062421A (ja) * 2006-07-12 2015-04-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達
JP2013534521A (ja) * 2010-06-22 2013-09-05 デエヌア・テラプーティック 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化ｉｎｖｉｖｏ送達システム
JP2014516977A (ja) * 2011-05-27 2014-07-17 アンスティテュ・キュリ 二本鎖切断を模倣するｄｎａ分子と温熱療法との組み合わせによるガンの処置
JP2016537027A (ja) * 2013-11-06 2016-12-01 ソルスティス バイオロジクス，リミティッド ジスルフィド基を有するポリヌクレオチド構築物
US11981703B2 (en) 2016-08-17 2024-05-14 Sirius Therapeutics, Inc. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
WO2019039403A1 (fr) * 2017-08-22 2019-02-28 国立大学法人名古屋大学 Polynucléotide modifié
US11236334B2 (en) 2017-08-22 2022-02-01 National University Corporation Nagoya University Modified polynucleotide

Also Published As

Publication number Publication date
WO1991014696A1 (fr) 1991-10-03
AU7759291A (en) 1991-10-21
EP0537299A1 (fr) 1993-04-21
CA2079109A1 (fr) 1991-09-30
EP0537299A4 (fr) 1993-02-05

Similar Documents

Publication Publication Date Title
JPH05505941A (ja) オリゴヌクレオチド―輸送剤ジスルフィド結合体
JP6758335B2 (ja) テロメラーゼ阻害のための改変オリゴヌクレオチド
US5214136A (en) Anthraquinone-derivatives oligonucleotides
EP0462145B1 (fr) Conjugue covalent de lipides et d'oligonucleotides
JP3529135B2 (ja) 特定のｒｎａ鎖の切断方法
US5994517A (en) Ligands to enhance cellular uptake of biomolecules
US20070161587A1 (en) Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
US8440635B2 (en) Oligonucleotide conjugates
JP2735813B2 (ja) 標的ポリヌクレオチドにハイブリッド形成するための新規な一工程方法とポリヌクレオチド化合物
US20030119724A1 (en) Ligands to enhance cellular uptake of biomolecules
US8420396B2 (en) Conjugates and processes for their preparation and their use for transporting molecules across biological membranes
JPH05505101A (ja) オリゴヌクレオチド療法における三重らせん形成
JP2002510319A (ja) オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
WO1991013080A1 (fr) Pseudonucleosides, pseudonucleotides et leurs polymeres
CN105392488A (zh) 用于调节载脂蛋白c-iii表达的组合物和方法
JPH06508022A (ja) 生体分子に特異的なアプタマーおよび生産方法
JP4854913B2 (ja) オリゴヌクレオチド結合体
WO2003025139A2 (fr) Administration d'acides nucleiques, d'analogues et de derives de ceux-ci induite par cobalamine
CHOW et al. Specific targeting of antisense oligonucleotides to neutrophils
JPH08506734A (ja) ｍＲＮＡキャップ活性に干渉しおよび翻訳を阻害するアンチセンスオリゴ類
AU2003244338C1 (en) Oligonucleotide conjugates
Murad et al. Gene Therapy